Dose Escalation Study of MLN4924 in Adults With Melanoma
| Status: | Archived |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2009 |
| End Date: | November 2011 |
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the
safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2
dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.
We found this trial at
1
site
Click here to add this to my saved trials
